FAQ on Soligenix Inc.'s Clinical Programs and Upcoming Trial Results

What is Soligenix Inc. focusing on in its clinical programs?

Soligenix Inc. is focusing on developing and commercializing treatments for rare diseases with significant unmet medical needs, including HyBryte(TM) for CTCL, SGX945 for Behçet’s disease, and SGX302 for psoriasis.

When are the top-line results from the phase 3 study of HyBryte(TM) expected?

The top-line results from the phase 3 confirmatory study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma are anticipated in 2026.

What are the upcoming milestones for Soligenix Inc.?

Upcoming milestones include top-line results in the second half of 2025 from phase 2 studies of SGX945 in Behçet’s disease and SGX302 in mild-to-moderate psoriasis, and phase 3 results for HyBryte(TM) in 2026.

What is HyBryte(TM) and what is it used for?

HyBryte(TM), also known as SGX301 or synthetic hypericin, is a novel photodynamic therapy using safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

How does Soligenix Inc. support its Public Health Solutions business segment?

The Public Health Solutions business segment is supported by government grants and contract funding from NIAID, DTRA, and BARDA, focusing on vaccine programs like RiVax(R) for ricin toxin and CiVax(TM) for COVID-19.

Where can I find more information about Soligenix Inc.?

For more information, visit Soligenix’s website at www.Soligenix.com or their newsroom at https://ibn.fm/SNGX.

What is the significance of Soligenix Inc.’s clinical programs?

Soligenix’s clinical programs aim to address significant unmet medical needs in rare diseases, offering potential new treatments for conditions like CTCL, Behçet’s disease, and psoriasis, with the anticipation of regulatory approvals and commercialization.

Who is leading Soligenix Inc.?

Christopher J. Schaber, PhD, is the CEO and president of Soligenix Inc., leading the company’s strategic focus on advancing its clinical programs.